TRDA
Company Description
Entrada Therapeutics, Inc. operates as a biotechnology enterprise dedicated to pioneering endosomal escape vehicle (EEV) therapeutics, specifically engineered to tackle a range of neuromuscular ailments. The company leverages its proprietary EEV platform to cultivate a rich pipeline of therapeutic programs, integrating oligonucleotide, antibody, and enzyme-based approaches. Its foremost product candidate, ENTR-601-44, is currently undergoing preclinical assessment for its potential in addressing both Duchenne muscular dystrophy and myotonic dystrophy type 1. Furthermore, Entrada is actively developing EEV-PMO-CAG, also targeting myotonic dystrophy type 1. Incorporated in 2016, the firm was formerly known as CycloPorters, Inc., before officially changing its name to Entrada Therapeutics, Inc. in October 2017. The company maintains its corporate headquarters in Boston, Massachusetts.
Track Record
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Revenue | 25.42M | 210.78M | 129.01M | 0 | 0 | 0 | 0 |
| Net Income | (143.75M) | 65.63M | (6.68M) | (94.62M) | (51.16M) | (26.52M) | (4.65M) |
| EPS | -3.47 | 1.76 | -0.20 | -2.79 | -1.60 | -0.84 | -4.44 |
| Free Cash Flow | (129.55M) | (44.72M) | 134.19M | (96.67M) | (55.44M) | (27.89M) | (11.43M) |
| FCF / Share | -3.13 | -1.20 | 4.06 | -3.09 | -1.78 | -0.89 | -10.91 |
| Operating CF | (128.51M) | (41.56M) | 139.80M | (93.79M) | (50.86M) | (25.57M) | (10.80M) |
| Total Assets | 377.38M | 526.32M | 469.19M | 252.06M | 305.83M | 43.53M | 18.24M |
| Total Debt | 50.93M | 59.21M | 68.23M | 25.94M | 0 | 0 | 0 |
| Cash & Equiv | 90.39M | 101.21M | 67.60M | 45.16M | 291.06M | 39.05M | 16.84M |
| Book Value | 306.13M | 428.68M | 242.36M | 212.55M | 298.72M | (41.49M) | (15.52M) |
| Return on Equity | -0.47 | 0.15 | -0.03 | -0.45 | -0.17 | N/A | N/A |
| Metric | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 898,000 | 875,000 | 1.30M | 1.61M | 1.95M | 20.56M | 37.40M | 19.57M | 94.69M | 59.12M | 41.85M | 43.73M |
| Net Income | (42.76M) | (39.72M) | (39.16M) | (44.13M) | (43.10M) | (17.35M) | 1.13M | (14.03M) | 55.03M | 23.50M | (9.54M) | 35.46M |
| EPS | -1.01 | -0.95 | -0.95 | -1.06 | -1.04 | -0.42 | 0.03 | -0.35 | 1.61 | 0.70 | -0.29 | 1.07 |
| Free Cash Flow | (32.47M) | (41.74M) | (32.00M) | (28.14M) | (29.76M) | (39.65M) | (32.24M) | (24.91M) | 38.79M | (26.36M) | (4.99M) | (25.94M) |
| FCF / Share | -0.77 | -1.00 | -0.77 | -0.68 | -0.72 | -0.97 | -0.79 | -0.61 | 1.13 | -0.79 | -0.15 | -0.78 |
| Operating CF | (32.46M) | (41.70M) | (32.20M) | (28.31M) | (29.49M) | (38.51M) | (31.61M) | (24.27M) | 39.83M | (25.52M) | (4.01M) | (24.49M) |
| Total Assets | 298.88M | 335.52M | 377.38M | 412.90M | 448.78M | 486.48M | 526.32M | 554.59M | 581.96M | 510.84M | 469.19M | 485.03M |
| Total Debt | 48.54M | 49.75M | 50.93M | 52.40M | 54.74M | 57.00M | 59.21M | 61.31M | 64.44M | 66.43M | 68.23M | 69.07M |
| Cash & Equiv | 99.28M | 76.44M | 90.39M | 93.29M | 72.48M | 67.84M | 101.21M | 78.05M | 185.25M | 68.44M | 67.60M | 51.88M |
| Book Value | 233.41M | 270.85M | 306.13M | 340.72M | 379.50M | 417.26M | 428.68M | 422.45M | 429.93M | 269.37M | 242.36M | 246.66M |
| Return on Equity | -0.18 | -0.15 | -0.13 | -0.13 | -0.11 | -0.04 | 0.00 | -0.03 | 0.13 | 0.09 | -0.04 | 0.14 |
